In conclusion, preoperative [18F]FDG PET/CT demonstrated considerable potential for evaluating the efficacy of NAC in BC patients across different subtypes and HER2 expression patterns, regardless of the treatment response classification. This evidence concerns the gene ERBB2 and breast cancer.